Table: Santen Pharm -2023/24 group results (IFRS)

SANTEN PHARMACEUTICAL

09/05/2024 07:00

May 9 (Reuters)- 
              Santen Pharmaceutical Co Ltd 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   Year ended      Year ended       Year to        NEXT  
                Mar 31, 2024    Mar 31, 2023   Mar 31, 2025      YEAR    
                   LATEST         YEAR-AGO        COMPANY      COMPANY   
                   RESULTS         RESULT        FORECAST    H1 FORECAST 
  Sales            301.97          279.04         297.00                 
                 (+8.2 pct)      (+4.8 pct)     (-1.6 pct)               
  Operating         38.54         loss 3.09        44.50                 
                                                (+15.5 pct)              
  Pretax            29.87         loss 5.80        45.00                 
                                                (+50.6 pct)              
  Net               26.64        loss 14.95                              
  EPS Basic       72.59 yen    loss 38.60 yen    92.22 yen               
  EPS Diluted     72.37 yen    loss 38.60 yen                            
  Ann Div         33.00 yen       32.00 yen      34.00 yen               
  -Q2 Div         16.00 yen       16.00 yen      17.00 yen               
  -Q4 Div         17.00 yen       16.00 yen      17.00 yen               
 
  NOTE - Santen Pharmaceutical Co Ltd. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company.
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T